1.	Phase III Randomized Study of Vaccination with Ganglioside GM2 Conjugated to Key Hole Limpet Hemocyanin plus Immunologic Adjuvant QS21 vs High Dose Interferon Alfa-2b in Patients with High Risk Melanoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: E-1694, CAN-NCIC-ME9, MDA-DM-E1694, MSKCC-96008, SWOG-9512, CAN-NCIC-E1694, MSKCC-E1694, SWOG-E1694, E1694, ME9
2.	Phase III Multicenter, Randomized, Controlled Study of THERATOPE Vaccine in Women With Metastatic Breast Cancer (Summary Last Modified 05/2001) Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BIOMIRA-STn-BR-104, NCI-V98-1489, NCT00003638
3.	Phase III Randomized Study of BCI-ImmuneActivator™ (Keyhole Limpet Hemocyanin) Versus Doxorubicin in BCG Refractory or Intolerant Patients With Carcinoma in Situ With or Without Resected Superficial Papillary Bladder Cancer Phase: Phase III Type: Treatment Status: Temporarily closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: INTRACEL-BCI-9804-04, NCT00006034
4.	Phase III Randomized Study of Cyclophosphamide, Prednisone, and Vincristine Followed By Immunotherapy With Keyhole Limpet Hemocyanin With or Without Recombinant Autologous Tumor-Derived Immunoglobulin Idiotype and Adjuvant Sargramostim (GM-CSF) in Patients With Stage III or IV Follicular B-Cell Non-Hodgkin's Lymphoma Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GENITOPE-G2000-03, CUMC-0101-142, UCLA-0010061, NCT00017290
5.	Phase I/II Pilot Study of Anti-Idiotypic MOAB BEC2 Conjugated to KLH plus BCG as Adjuvant in Completely Resected Melanoma (Summary Last Modified 03/95) Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-94078, NCI-H94-0538
6.	Dendritic Cell Based Therapy of Renal Cell Carcinoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: UR0414, NCT00197860
7.	Dendritic Cell Based Therapy of Malignant Melanoma Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: MM0413, NCT00197912
8.	Phase II Study of Tumor-Derived Immunoglobulin Idiotype Vaccination and Sargramostim following Cyclophosphamide/Doxorubicin/Etoposide/Prednisone in Low-Grade Follicular Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-96-C-0133, CRB-9309, NCI-T93-0164N, T93-0164, NCT00878488
9.	Phase II Randomized, Double-Blind Study of 3 Doses of Sialyl Tn-KLH Therapeutic Vaccine with Detox B Adjuvant as Active-Specific Immunotherapy for Colorectal Cancer (Summary Last Modified 05/98) Phase: Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Other Protocol IDs: UNMC-04094, NCI-V94-0589
10.	Phase II Study of Active Immunization of Related Bone Marrow Transplant Donors Against Purified Myeloma Protein from the Recipient Undergoing Allogeneic Bone Marrow Transplantation Phase: Phase II Type: Treatment Status: Completed Age: under 60 Sponsor: NCI Protocol IDs: NCI-97-C-0030B, CRB-9407, NCI-T94-0085N, T94-0085
11.	Phase II Study of Autologous Myeloma-Derived Immunoglobulin Idiotype Conjugated to Keyhole Limpet Hemocyanin Plus Sargramostim (GM-CSF) in Patients With Multiple Myeloma Undergoing Second Autologous Peripheral Blood Stem Cell Transplantation Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-97-C-0033B, CRB-9409, NCI-T94-0094N, T94-0094, NCT00019097
12.	Phase II Study of Allogeneic T-Cell-Depleted BMT, Followed by Transplantation of Allogeneic T Cells from Idiotype-Vaccinated Donors, for Multiple Myeloma (Summary Last Modified 04/98) Phase: Phase II Type: Treatment Status: Completed Age: 18 to 60 Sponsor: NCI, NHLBI Protocol IDs: NHLBI-T96-0017, NCI-T96-0017N, T96-0017
13.	Phase II Study of Vaccination with Tn(c)-KLH Conjugate Plus the Immunological Adjuvant QS21 in Patients with Prostate Cancer (Summary Last Modified 05/1999) Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-98002, NCI-G98-1440
14.	Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: Over 18 Sponsor: NCI, Other Protocol IDs: 197-99, P30CA036727, UNMC-197-99, GENITOPE-9902, SUMC-9902, NCT00004197
15.	Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Completed Age: Over 18 Sponsor: NCI, Other Protocol IDs: 196-99, P30CA036727, UNMC-196-99, GENITOPE-9901, NCT00004198
16.	Phase II Study of Immunization With Polysialic Acid Keyhole Limpet Hemocyanin (PSA-KLH) Conjugate or N-Propionylated PSA-KLH Hemocyanin Conjugate Plus Immunological Adjuvant QS21 in Patients With Small Cell Lung Cancer With Complete or Partial Response to Initial Therapy Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-98065, NCI-H99-0047, NCT00004249
17.	Chemotherapy Plus Vaccination to Treat Mantle Cell Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: 000133, 00-C-0133, NCI-00-C-0133, NCI-1033, NCT00020215, NCT00005780
18.	Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma Phase: Phase II Type: Treatment Status: Closed Age: 18 to 75 Sponsor: NCI Protocol IDs: 000201, 00-C-0201, NCI-00-C-0201, NCI-1029, 1029, NCT00020306, NCT00006184
19.	Phase II Study of Autologous Tumor Cell Vaccine With Adjuvant Sargramostim (GM-CSF) in Patients With Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: FAV-ID-01, SKCC-2001, SKCC-BB-IND-8786
20.	Phase II Pilot Adjuvant Study of Vaccination with Sialyl Tn Antigen Covalenty Attached to KLH plus Detox in Patients with High-Risk Resected Colorectal Cancer Phase: Phase II Type: Treatment Status: Completed Age: any age Sponsor: Protocol IDs: MSKCC-91095, NCI-V91-0167
21.	Phase II Pilot Study of Vaccination with Sialyl Tn Antigen Covalently Attached to KLH plus QS21 in High-Risk Resected Colorectal Cancer (Summary Last Modified 07/95) Phase: Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: MSKCC-92100, NCI-V92-0144
22.	Phase II Pilot Study of Vaccination with GD3 Covalently Attached to KLH plus the Immunological Adjuvant QS21 in Patients with Resected Stage III/IV Melanoma (Summary Last Modified 06/93) Phase: Phase II Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: MSKCC-92168, NCI-V93-0228
23.	Phase II Pilot Study of Vaccination with GD2 Covalently Attached to KLH plus the Immunological Adjuvant QS21 in Patients with Resected High-Risk Stage III/IV Melanoma (Summary Last Modified 06/93) Phase: Phase II Type: Treatment Status: Completed Age: no age specified Sponsor: Protocol IDs: MSKCC-92169, NCI-V93-0229
24.	Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: UARK 2000-46, NCT00083538
25.	Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000389145, STLMC-IMM-03-05, STLMC-L-03-138, NCT00093522